Replies to post #251143 on Biotech Values

[DewDiligence]

NVS acquires TRML for $48/sh cash—a 59% premium to yesterday’s close:

https://www.globenewswire.com/news-release/2025/09/09/3146562/0/en/Tourmaline-Bio-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG.html

The nominal deal value is $1.4B. TRML is the product of a 2023 reverse-merger (#msg-173043164).